A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Donna Ellen Reece; Nizar J. Bahlis; Christy Joy Samaras; Michael Sebag; Jesus G. Berdeja; Siddartha Ganguly; Jeffrey Matous; Kevin W. Song; Christopher Seet; Giampaolo Talamo; Mirelis Acosta-Rivera; Michael Bar; Donald Quick; Bertrand Marquess Anz; Gustavo A. Fonseca; Amit Agarwal; Weiyuan Chung; Faiza Zafar; David Samuel DiCapua Siegel

doi:10.1200/JCO.2019.37.15_SUPPL.8025

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Donna Ellen Reece
, Nizar J. Bahlis
, Christy Joy Samaras
, Michael Sebag
, Jesus G. Berdeja
, Siddartha Ganguly
, Jeffrey Matous
, Kevin W. Song
, Christopher Seet
, Giampaolo Talamo
, Mirelis Acosta-Rivera
, Michael Bar
, Donald Quick
, Bertrand Marquess Anz
, Gustavo A. Fonseca
, Amit Agarwal
, Weiyuan Chung
, Faiza Zafar
, David Samuel DiCapua Siegel

Princess Margaret Hospital, Toronto, ON, Canada;
University of Calgary
Cleveland Clinic
McGill University Health Centre
Sarah Cannon Research Institute
University of Kansas
Colorado Blood Cancer Institute, Denver, CO;
Vancouver General Hospital
UCLA Medical Center
Penn State Cancer Institute
Fundación de Investigación Oncology Trials, San Juan, PR;
Stamford Hospital
Joe Arrington Cancer Research and Treatment Center, Lubbock, TX;
Tennessee Oncology, Chattanooga, TN;
Florida Cancer Specialists, Saint Petersburg, FL;
Celgene
Hackensack University Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8025
State	Published - May 26 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2019.37.15_SUPPL.8025License: Unspecified

Cite this

Reece, D. E., Bahlis, N. J., Samaras, C. J., Sebag, M., Berdeja, J. G., Ganguly, S., Matous, J., Song, K. W., Seet, C., Talamo, G., Acosta-Rivera, M., Bar, M., Quick, D., Anz, B. M., Fonseca, G. A., Agarwal, A., Chung, W., Zafar, F., & Siegel, D. S. D. (2019). A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment. Journal of Clinical Oncology, 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8025

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment. / Reece, Donna Ellen; Bahlis, Nizar J.; Samaras, Christy Joy et al.
In: Journal of Clinical Oncology, Vol. 37, 26.05.2019.

Research output: Contribution to journal › Article › peer-review

Reece, DE, Bahlis, NJ, Samaras, CJ, Sebag, M, Berdeja, JG, Ganguly, S, Matous, J, Song, KW, Seet, C, Talamo, G, Acosta-Rivera, M, Bar, M, Quick, D, Anz, BM, Fonseca, GA, Agarwal, A, Chung, W, Zafar, F & Siegel, DSD 2019, 'A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.', Journal of Clinical Oncology, vol. 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8025

@article{709afc36928541ba9d90eb326ac40fee,

title = "A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.",

author = "Reece, \{Donna Ellen\} and Bahlis, \{Nizar J.\} and Samaras, \{Christy Joy\} and Michael Sebag and Berdeja, \{Jesus G.\} and Siddartha Ganguly and Jeffrey Matous and Song, \{Kevin W.\} and Christopher Seet and Giampaolo Talamo and Mirelis Acosta-Rivera and Michael Bar and Donald Quick and Anz, \{Bertrand Marquess\} and Fonseca, \{Gustavo A.\} and Amit Agarwal and Weiyuan Chung and Faiza Zafar and Siegel, \{David Samuel DiCapua\}",

note = "8025 Background: Treatment (Tx) of RRMM is complex and requires evaluation of disease and patient (pt) factors to maximize efficacy and minimize toxicity. HRQoL has become an important aspect of MM Tx, as survival has improved with therapeutic advances.",

year = "2019",

month = may,

day = "26",

doi = "10.1200/JCO.2019.37.15\_SUPPL.8025",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

AU - Reece, Donna Ellen

AU - Bahlis, Nizar J.

AU - Samaras, Christy Joy

AU - Sebag, Michael

AU - Berdeja, Jesus G.

AU - Ganguly, Siddartha

AU - Matous, Jeffrey

AU - Song, Kevin W.

AU - Seet, Christopher

AU - Talamo, Giampaolo

AU - Acosta-Rivera, Mirelis

AU - Bar, Michael

AU - Quick, Donald

AU - Anz, Bertrand Marquess

AU - Fonseca, Gustavo A.

AU - Agarwal, Amit

AU - Chung, Weiyuan

AU - Zafar, Faiza

AU - Siegel, David Samuel DiCapua

N1 - 8025 Background: Treatment (Tx) of RRMM is complex and requires evaluation of disease and patient (pt) factors to maximize efficacy and minimize toxicity. HRQoL has become an important aspect of MM Tx, as survival has improved with therapeutic advances.

PY - 2019/5/26

Y1 - 2019/5/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8025

U2 - 10.1200/JCO.2019.37.15_SUPPL.8025

DO - 10.1200/JCO.2019.37.15_SUPPL.8025

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Disciplines

Access to Document

Other files and links

Cite this